139 related articles for article (PubMed ID: 36741253)
1. Cancer-directed surgery brings survival benefits for patients with advanced prostate cancer: a population-based propensity-score matching study.
Chen R; Lu Y; Horie S; Vogel M; Zhang R; Zheng P; Wei Y
J Cancer; 2023; 14(2):231-238. PubMed ID: 36741253
[No Abstract] [Full Text] [Related]
2. A population-based propensity score matching analysis of risk factors and the impact on survival associated with refusal of cancer-directed surgery in patients with prostate cancer.
Tang Y; Gao Y; Zhang R; Li T; Yang Y; Huang L; Wei Y
Sci Rep; 2024 Apr; 14(1):9494. PubMed ID: 38664545
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of radical prostatectomy in patients with advanced TURP-diagnosed prostate cancer: a population-based real-world study.
Lin D; Lin L; Ye L; Li T; Wei Y; Li L
BMC Surg; 2024 May; 24(1):134. PubMed ID: 38702689
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score-matching Study.
Wei Y; Kobayashi T; Lu Y; Vogel M; Zhang R; Wu J; Gao Y; Lin L; Zhu Q; Ye L; Horie S; Wang X; Li T
Eur Urol Open Sci; 2022 Dec; 46():88-95. PubMed ID: 36506256
[TBL] [Abstract][Full Text] [Related]
5. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of surgical resection for stage IV gastric cancer: A SEER-based propensity score-matched analysis.
Sun J; Nan Q
Front Surg; 2022; 9():927030. PubMed ID: 36386506
[TBL] [Abstract][Full Text] [Related]
7. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
Prostate; 2022 May; 82(6):740-750. PubMed ID: 35226380
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer characteristics and cancer-specific mortality of Native American patients.
Deuker M; Knipper S; Pecoraro A; Palumbo C; Rosiello G; Luzzago S; Tian Z; Saad F; Chun F; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):277-285. PubMed ID: 31695139
[TBL] [Abstract][Full Text] [Related]
9. The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database.
Yuan QM; Lin TH; Jin K; Qiu S; Zhou XH; Jin D; Li JK; Yang L; Wei Q
Asian J Androl; 2022; 24(3):305-310. PubMed ID: 34596600
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.
Gandaglia G; Sun M; Trinh QD; Becker A; Schiffmann J; Hu JC; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI; Abdollah F
BJU Int; 2014 Dec; 114(6b):E62-E69. PubMed ID: 24467651
[TBL] [Abstract][Full Text] [Related]
11. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
Sheng W; Kirschner-Hermanns R; Zhang H
World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
[TBL] [Abstract][Full Text] [Related]
12. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
[TBL] [Abstract][Full Text] [Related]
13. Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis.
Pausch TM; Liu X; Cui J; Wei J; Miao Y; Heger U; Probst P; Heap S; Hackert T
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008223
[TBL] [Abstract][Full Text] [Related]
14. Cryotherapy shows no inferiority compared with radical Prostatectomy for low-risk and intermediate-risk localized Prostate Cancer: a real-world study from the SEER database.
Jin K; Qiu S; Zheng X; Li Y; Zhang S; Li J; Liao X; Tu X; Yang L; Wei Q
J Cancer; 2020; 11(19):5738-5745. PubMed ID: 32913467
[No Abstract] [Full Text] [Related]
15. How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?
Jin K; Qiu S; Li J; Zheng X; Tu X; Liao X; Yang Y; Yang L; Wei Q
Cancer Med; 2019 Jul; 8(7):3370-3378. PubMed ID: 31066510
[TBL] [Abstract][Full Text] [Related]
16. PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions.
Deuker M; Stolzenbach LF; Pecoraro A; Rosiello G; Luzzago S; Tian Z; Saad F; Chun FK; Karakiewicz PI
World J Urol; 2021 Mar; 39(3):787-796. PubMed ID: 32458094
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics.
Abdollah F; Karakiewicz PI; Gandaglia G; Dalela D; Klett DE; Shiffmann J; Montorsi F; Briganti A; Saad F; Graefen M; Peabody JO; Menon M; Sun M
Eur Urol Focus; 2015 Sep; 1(2):191-199. PubMed ID: 28723433
[TBL] [Abstract][Full Text] [Related]
18. Influencing factors for mortality in prostate cancer patients with T1 and T2 stage: a retrospective cohort study.
Hong X; Cao S; Chi Z; Zhang Y; Lin T; Zhang Y
Transl Androl Urol; 2023 Jan; 12(1):58-70. PubMed ID: 36760871
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients.
Bandini M; Preisser F; Nazzani S; Marchioni M; Tian Z; Fossati N; Gandaglia G; Gallina A; Abdollah F; Shariat SF; Montorsi F; Saad F; Tilki D; Briganti A; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):381-388. PubMed ID: 29366856
[TBL] [Abstract][Full Text] [Related]
20. Analysis of survival and prognostic factors of clear cell adenocarcinoma of the prostate: a case-control study for a rare cancer entity.
Chen S; Song W; Zhang R; Jin Y; Lu Y; Lin L; Ye L; Li T; Wei Y
Sci Rep; 2023 Jun; 13(1):10317. PubMed ID: 37365217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
